Rationale: IL-18 is a member of the IL-1 cytokine family, and elevated blood IL-18 concentrations associate with disease activity in macrophage activation syndrome (MAS) and poor clinical outcomes in severe inflammatory and septic conditions.
Hyperinflammatory conditions are lifethreatening complications resulting from a systemic proinflammatory response triggered by infection, injury, or chronic inflammation (1, 2) . In critically ill children, the current state of knowledge suggests a significant immunophenotype overlap of hyperferritinemic sepsis-related multiple organ dysfunction syndrome, macrophage activation syndrome (MAS), and secondary hemophagocytic lymphohistiocytosis (sHLH) (3) . Excessive expression of cytokines such as TNFa (tumor necrosis factor a), IL-1b, and IL-6 plays a pivotal role in the very early response of innate immune cells to infection or trauma in such conditions, but later release of these proinflammatory cytokines can be impaired by a state termed "sepsis-induced immunoparalysis" or, as the experimental analog to this clinical entity, "endotoxin tolerance" (4) .
Although TNFa, IL-1b, and IL-6 are potent inflammatory mediators, the IL-1 family cytokine IL-18 has recently been suggested as the critical driver of MAS (5, 6) , a severe hyperinflammatory condition characterized by a catastrophic cytokine storm resulting in multiple organ failure and high mortality. MAS is a known complication of chronic rheumatic diseases in childhood and is particularly associated with systemic juvenile idiopathic arthritis (sJIA) but also can result from bacterial or viral infections (sHLH) (7) or complicate sepsis (macrophage activation-like syndrome) (3, 4, 8) . Elevated IL-18 concentrations in serum or plasma have been shown to be associated with severity of disease in MAS (5, 9) and poor clinical outcomes in severe inflammatory and septic conditions (10) . Inhibition of IL-18 receptor signaling reduced inflammation in a mouse model of MAS (6) , and treatment with IL-18BP (recombinant human IL-18 binding protein) can improve clinical outcome (11, 12) . Similarly, targeting IL-18 in addition to neutralizing IL-1b rescued mice from inflammatory and septic shock (13) .
Unlike conventional inflammatory cytokines such as TNFa or IL-6, IL-1b and IL-18 are expressed as inactive propeptides (proIL-1b, proIL-18) by monocytes, macrophages, and neutrophils following the stimulation of pattern recognition receptors such as TLRs (Tolllike receptors) by pathogen-or damageassociated molecular patterns. Both IL-1b and IL-18 propeptides then require inflammasome-mediated caspase cleavage to be secreted as mature bioactive proteins (14) . In contrast to IL-1b, IL-18 secretion does not necessarily require de novo protein synthesis and rather is thought to be facilitated from a premade pool of cytoplasmic pro-and mature IL-18 (15, 16) .
In contrast to recent advances in understanding the pathophysiologic contribution of IL-18 to (hyper) inflammation, cellular control over IL-18 expression remains poorly understood. Although the regulation of IL-1b expression highlights a critical role for NFkb (nuclear factor kb) (17) (18) (19) (20) (21) (22) (23) , current studies on murine (24, 25) or human (25-28) cells do not provide conclusive evidence on whether and how IL-18 expression is controlled (14) . In this study we demonstrated that, in contrast to TNFa, IL-6, and IL-1b, expression of human IL-18 can escape LPSinduced in vivo immunoparalysis and endotoxin tolerance. This is facilitated by the specific monocytic transcription kinetics of IL-18, which are controlled by cooperative type I IFN and TLR signaling. JAK/STAT inhibition in sHLH/MAS mouse models and in a treatment-refractory patient with MAS greatly reduced IL-18 serum levels and controlled MAS. Consequently, our study addresses a missing link in understanding MAS pathogenesis by providing an explanation for the clinical experience suggesting an association of MAS in autoinflammatory patients with viral infections (8, 29) . In turn, this result favors JAK/STAT inhibition as a therapeutic option to control disease. Some results of these studies have been reported previously in the form of abstracts (30, 31) .
Methods

Human Study Subjects
The study protocol for the in vivo endotoxin rechallenge was approved by the ethics committee of the Radboud University Nijmegen Medical Center and complies with the Declaration of Helsinki and good clinical practice guidelines. Healthy male volunteers gave written informed consent. Experiments were part of a larger endotoxin trial (ClinicalTrials.gov identifier NCT01374711). Patients with inflammatory disease provided written informed consent, and all studies were approved by the ethics committee of Muenster University hospital or the Cincinnati Children's Hospital Medical Center.
Mice
Wild-type (C57BL/6-J) mice were purchased from the Jackson Laboratory. Experimental mice were sex and age matched and used at 8-16 weeks of age. Mice were housed in a specific pathogenfree facility at St. Jude Children's Research Hospital. Experiments were conducted under the approval of the institutional animal care and use committee.
In Vivo Endotoxin Rechallenge
Plasma samples were obtained from an in vivo experimental endotoxemia rechallenge trial (32, 33) . Further details are provided in the online supplement. Experimental design and blood sampling time points are depicted in Figure 1A .
Human Monocyte Isolation, Culture, and Stimulation
Detailed description is provided in the online supplement.
Quantitative Real Time-PCR Type 1 IFN Score and Secreted Cytokine Quantification
Methods are outlined in detail in the online supplement.
At a Glance Commentary
Scientific Knowledge on the Subject: The IL-1 cytokine family member IL-18 is thought to play a key role in the pathogenesis of (hyper) inflammation in macrophage activation syndrome (MAS) and sepsis. However, regulatory mechanisms underlying human IL-18 expression remain poorly understood.
What This Study Adds to the Field:
We demonstrate that IL-18 expression from human monocytes is orchestrated by synergistic Toll-like receptor and type I IFN signaling. Interference with JAK/STAT signaling can blunt IL-18 production and thus may help to control hyperinflammation in MAS. Serum IL-18 levels were quantified from mice in sHLH/MAS models with and without ruxolitinib treatment, as described in studies by Albeituni and colleagues (34) and Weaver and colleagues (35) . Mouse models and the IL-18 ELISA procedure are detailed in the online supplement.
Statistical Analysis
Data were analyzed using GraphPad Prism software (v8.0, Mac OSX; GraphPad Software), as indicated in figure legends and described in the online supplement.
Results
Human IL-18 Expression Escapes Immunoparalysis and Endotoxin Tolerance
Our studies on IL-18 were primed by observations on cytokine expression from in vivo and in vitro endotoxin desensitization experiments. In plasma of healthy individuals who underwent repeated endotoxemia experiments (32) ( Figure 1A ), we initially observed that IL-18 levels remained unaffected by endotoxin tolerance ( Figures 1B and 1C) , in contrast to other cyto-or chemokines, particularly TNFa, IL-6, and IL-1b. Similarly, in TLR4 desensitization experiments on primary human monocytes ( Figure 1D ), we observed that gene expression of inflammatory cytokines was blunted by repeated TLR4 stimulation. IL18 expression, however, seemed to be induced by repeated LPS challenge ( Figure 1D ). With further investigation, we wondered whether human IL-18 transcription might follow different time kinetics than other inflammatory cytokines. When stimulating human monocytes with LPS, we observed that TNFA, IL1B, and IL6 revealed maximum expression at 4 hours following endotoxin challenge; however, IL18 expression was delayed and reached its maximum at approximately 17 hours after LPS challenge ( Figure 2A ). In contrast, cytokine release by LPS-and ATPstimulated monocytes occurred readily and peaked at 4 hours after cell stimulation ( Figure 2B ). LPS rechallenge of monocytes at the peak of IL18 expression at 17 hours ( Figure 2A) Figure 2C ). Therefore, the delayed IL18 gene expression pattern may allow cells to repeatedly mount IL-18 release despite endotoxin tolerance.
Interfering with JAK/STAT and Particularly Type I IFN Signaling Reduces IL18 Expression
We next aimed at understanding the reason for the delayed IL18 expression kinetics. Because prominent inflammatory cytokines such as TNFa, IL-1b, or IL-6 were expressed and released early on LPS stimulation of human monocytes, we wondered whether they, rather than LPS signaling, might be responsible for inducing IL18 expression and thus explain its delayed kinetics. Monocytes were pretreated with antiinflammatory drugs neutralizing either IL-1b or TNFa or blocking the IL-1 or IL-6 receptor, followed by LPS stimulation. We observed that TNFa blockade negatively affected IL1B expression; however, none of the applied treatments revealed any effect on IL18 expression ( Figures 3A and E1A in the online supplement). We also tested cytokine expression on monocyte treatment with tofacitinib, a JAK/STAT inhibitor approved for treatment of various inflammatory diseases (36) . Tofacitinib pretreatment followed by LPS stimulation strongly enhanced monocytic TNFA, IL6, and particularly IL1B expression ( Figures 3A and  E1A ). In contrast, JAK/STAT inhibition significantly reduced IL-18 gene expression ( Figure 3A ). As an inhibitor of JAK1/3 but also JAK2, tofacitinib can impair downstream phosphorylation of several STAT proteins (36, 37) . Flow cytometry demonstrated that IFNa induced strong STAT1 phosphorylation, which was impaired by tofacitinib ( Figures  E1B and E1C ). In these assays, short-term stimulation with LPS also induced some STAT1 phosphorylation, which was equally sensitive to tofacitinib treatment ( Figures  E1B and E1C ). Cell stimulation with LPS can result in both the NFkb-dependent transcription of classical inflammatory cytokines and the IRF3-dependent expression of type I IFN (38, 39) . JAK/STAT-pathway activation can be induced by both cytokine and IFN signaling through their respective receptors. Because we did not observe any effect on IL18 expression when interfering with receptor signaling by prominent inflammatory cytokines, we decided to further study neutralization of type I IFN, which can be expressed following LPS stimulation (38, 39) . Treating endotoxin-stimulated monocytes with an IFNb-neutralizing antibody did not affect TNFA and IL6 transcription ( Figure E2A ) but increased IL1B expression by trend while greatly reducing IL18 expression in a concentration-dependent manner (Figures 3B and 3C and E2B). At that point, we concluded that interfering with type I IFN signaling in our LPS-stimulated monocyte cultures had strong but opposing effects on IL1b and IL18 gene expression.
Type I IFN Signaling Controls Monocytic IL-18 Expression
We next analyzed whether the release of IFNa/b on LPS stimulation controls monocytic IL18 expression and thus might be responsible for the initially observed delayed expression kinetics and repeated cytokine expression. To test this hypothesis, we costimulated monocytes with LPS and IFNa/b or subjected cells to IFN priming for either 4 or 16 hours before endotoxin treatment. Compared with just LPSstimulated cells, IFNa/b priming of monocytes enhanced IL1B, TNFA, and IL6 expression at its maximum around 4 hours following endotoxin treatment. Beyond 4 hours, IFNa/b priming significantly reduced IL1B transcription (Figures 4A and E3A and E3B). In contrast, IL18 expression was increased but, more important, IFNa/b priming of monocytes shifted the IL18 expression kinetics from its 17-hour maximum to peak expression at 4 hours after LPS stimulation. The longer monocytes were primed with either IFNa or IFNb, the more pronounced the shift in IL18 expression kinetics (Figures 4A and E3A and E3B). Compared with IFNa/b, we also costimulated or primed cells with IFNg. This increased TNFA and IL6 but revealed no effect on IL18 expression ( Figures 4B and E3C ). Apart from shifting IL18 expression kinetics, the priming of human monocytes with IFNa/b but not IFNg strongly increased IL-18 release on subsequent LPS stimulation. This effect was not observed with IL-1b ( Figure 4C ).
In addition to our in vitro data suggesting an involvement of STATmediated IFNa/b signaling in controlling IL-18 gene expression, we had the opportunity to investigate a patient with a not-yet-described gain-of-function mutation in STAT1 (STAT1 GOF , exon 10 c.838T . G p.Leu280Val) ( Figure 4D ). Although the patient's STAT1 expression was already increased at baseline, we observed no differences in IL1B expression on LPS stimulation compared with healthy control monocytes over time ( Figure 4D ). In contrast, the IL18 expression kinetics observed with STAT1 GOF monocytes differed from that of healthy controls ( Figure 4D ) and was shifted forward in a manner similar to IFNa/b-primed healthy monocytes ( Figure 4A ).
Monocytic IL18 Expression Requires Cooperative TLR and Type I IFN Signaling
Our data indicate that manipulation of IFNa/b signaling in LPS-stimulated monocyte cultures strongly affects IL18 expression. Therefore, we sought to test whether cell stimulation with just type I IFN would similarly induce IL18 expression. We also aimed to study cytokine expression following stimuli such as flagellin or IL-1b, which canonically induce NFkb activation via the MyD88dependent pathway (40) . In these assays, we observed that IFNa/b induced neither IL1B nor IL18 expression, whereas NFkb inhibition during LPS stimulation blunted IL1B and IL18 expression ( Figures 5A and  E4A ). Flagellin stimulation induced IL-1b gene expression similar to LPS, whereas rIL-1b triggered its own expression at comparably lower levels. In contrast, treatment of monocytes with flagellin or rIL-1b induced significantly less IL18 transcription than LPS ( Figure 5A ). Importantly, together with remnant IL18 expression on stimulation with flagellin, we also observed low-level induction of IFNb gene expression. In contrast, rIL-1b failed to induce IFNB transcription ( Figure 5B ). Maximum IFNB expression induced by either flagellin or LPS was observed after 2 hours of stimulation ( Figure 5B ) and strongly correlated with respective subsequent IL18 transcription ( Figure 5C ).
Microtubule-Destabilizing Drugs
Impair Monocytic IL18 Expression, Which Can Be Rescued by Type I IFN IL-18 serum levels are greatly increased in some autoinflammatory diseases such as familial Mediterranean fever (FMF) or sJIA and particularly sJIA-associated MAS or infection-associated sHLH (5, 41, 42) . Treatment with microtubule destabilizing agents (MDAs) such as colchicine can result in reduction of inflammation accompanied by decreasing IL-1b and IL-18 serum levels (41, 43, 44) . In our experiments, treatment of healthy donor monocytes with colchicine before LPS stimulation had no effect on IL-1b but increased IL-18 release ( Figure E4B) . At a gene-expression level, colchicine treatment of cells blunted IL18 expression, whereas IL1B expression was enhanced ( Figure 5D ). Apart from impairment of microtubule polymerization by colchicine, we also investigated the effect of nocodazole, a synthetic microtubule polymerization inhibitor, on IL-1b and IL-18 expression. We observed that, similar to colchicine treatment, nocodazole increased IL-18 release (Figure E4B) . At a gene-expression level, nocodazole amplified IL1B while abrogating IL18 expression ( Figure 5D ).
Because our data suggested that type I IFN controlled IL18 expression, we wondered how the observed MDAmediated impairment might fit in this picture. In fact, reports have suggested that colchicine treatment affects IFNa/b expression or its release (45, 46) . In our experiments, we found that IFNB gene expression peaked at 2 hours and protein secretion peaked at 3 hours following Figures 5E and  E4C ). To demonstrate that lack of type I IFN signaling in our MDA-treated cells was responsible for the observed abrogation of IL18 expression, we primed cells with IFNa/b alongside colchicine or nocodazole. Both MDA treatments and type I IFN treatment enhanced IL1B expression ( Figures 5F and  E5A and E5B ). This result was similarly true for IL6 ( Figures E5G and E5H) , whereas TNFA expression remained unaffected by MDAs and was amplified by type I IFN ( Figures E5E and E5F) . Strikingly, the addition of IFNa/b to MDA-treated cells was able to rescue LPS-induced IL18 expression ( Figures 5F and E5C and E5D ).
Blood Cell Expression of IL-18
Correlates with Type I IFN Score and Is Sensitive to In Vivo JAK/STAT Inhibition To further validate our findings, we analyzed IL18 compared with type I IFN stimulated gene (ISG15, RSAD2, IFIT1, IFI27, IFI44L, and SIGLEC1) expression in autoinflammatory diseases (FMF and sJIA) and polygenic interferonopathies (systemic lupus erythematosus [SLE] and juvenile dermatomyositis [JDM]) in patients' whole blood. In these ex vivo analyses, we observed a strongly significant correlation between type I IFN score and IL18 transcription ( Figure 6A ). Because we had no access to patient material before and after colchicine treatment to study the in vivo drug impact on type I IFN and IL-18 expression, we compared gene expression in the whole blood of patients with FMF or sJIA. Although these diseases differ in pathophysiology, they share prominent clinical phenotypes. When compared with samples from colchicine-treatmentnaive patients with sJIA, samples from colchicine-treated patients with FMF revealed significantly decreased type I IFN scores and IL18 expression ( Figure 6B ).
Up to this point, the majority of our analysis has focused on IL-18 gene expression. However, we anticipated that manipulations in type I IFN signaling such as JAK/STAT-inhibition would affect IL-18 serum levels and thus impact clinical outcome. To test this notion, we analyzed IL-18 serum levels in mice subjected to a model of moderate ( Figure 6C ) and fulminant ( Figure 6D ) sHLH/MAS, untreated or treated with the JAK1/2 inhibitor ruxolitinib. Mice repeatedly injected with CpG ( Figure 6C ) or CpG and an IL-10R-blocking antibody ( Figure 6D ) developed an inflammatory phenotype resembling sHLH/MAS (34, 35) . Compared with untreated animals, we detected markedly increased IL-18 serum levels in diseased mice ( Figures 6C and 6D) . In both models, ruxolitinib treatment significantly decreased total IL-18 serum levels (Figures 6C and 6D ) and improved clinical outcomes (34, 35) .
Finally, we analyzed serum IL-18 levels in a 7-year-old male patient with sJIA who presented with persistently active disease, with recurrent MAS and sJIA-associated lung disease unresponsive to IL-1 and IL-6 blockade. His frequent disease flares and recurrent episodes of MAS were reduced through use of recombinant human IL-18 binding protein (12), but he continued to have persistently elevated serum IL-18 levels of 50,000-120,000 pg/ml ( Figure 6E ). In an effort to improve control of his overall disease and lung disease in particular, he was started on the JAK1/3 inhibitor tofacitinib. He required dose reduction and holding of medication for an episode of anemia and for an acute infection. However, once on a stable dose of tofacitinib, his markers of inflammation including white blood cell count, ferritin, and CRP stabilized. Interestingly, his serum IL-18 levels, which had remained elevated even during periods of low disease activity, showed a sustained 67% decrease during tofacitinib therapy ( Figure 6E ). This result highlights the effect of JAK/STAT inhibition on IL-18 regulation despite treatment interruptions. These preliminary clinical data support a model in which IFN signaling has a key role in sustaining high levels of IL-18 expression in sJIA.
Discussion
Unopposed IL-18 signaling has been shown to trigger hyperinflammation in MAS (5, 6) and to play a key role in the pathogenesis of inflammatory and septic shock (13) . However, transcriptional control over IL-18 expression by monocytes as a primary source for release of bioactive cytokine is unknown. In this study, we demonstrated that-unlike TNFa, IL-6, and IL-1bhuman IL-18 expression escapes LPSinduced immunoparalysis and endotoxin tolerance. We found this could be due to delayed IL-18 gene expression kinetics, providing mRNA for repeated protein production. Furthermore, we showed that transcription of the IL-18 gene by human monocytes is orchestrated by inflammatory TLR and type I IFN signaling. MDAs such as colchicine that are used to treat diseases with a hallmark of IL-18 overexpression abrogate its transcription by interfering with type I IFN expression. IL18 expression correlates with type I IFN score in inflammatory disease patients, and JAK/STAT inhibition greatly decreases serum IL-18 levels in sHLH/MAS murine models and in a patient with treatment-refractory MAS.
Several studies have shown elevated IL-18 concentrations to be associated with disease activity in MAS (5, 9) or poor clinical outcome in severe inflammatory and septic conditions (10) . However, apart from our observations, we know of no human data on IL-18 expression in a context with LPS-induced immunoparalysis or endotoxin tolerance. Observations in mice mimic our findings, as serum or cellular IL-18 levels in animals rechallenged with LPS are reported to remain unaffected or to increase compared with mice receiving only single-endotoxin conditioning (47, 48) . When further studying possible contributors to the observed delayed IL18 gene expression, we identified a critical requirement of type I IFN for monocytic IL18 expression. Apart from our data on human cells, several studies suggest a relationship between IFNa/b signaling and IL-18 secretion in mice. In Ifnar 2/2 macrophages responding to Streptococcus pneumoniae infection, IFNa/b signaling has been observed to be required for IL-18 release (49) . Similarly, TRIF deficiency has been observed to abrogate both IL-1b and IL-18 release during systemic gramnegative infection (50) . However, both of these studies attribute their findings to IFNa/b-dependent inflammasome activation and caspase licensing rather than cytokine gene expression. Also focusing on IL18 gene expression rather than its secretion, a recent murine study by Zhu and Kanneganti (16) describes findings that are strikingly similar to our observations in human cells. After stimulation of bone marrow-derived macrophages with LPS, they also observed divergent kinetics in Il1b and Il18 expression. IL-18 but not IL-1b gene and propeptide expression was abrogated in Ifnar1 2/2 , Ifnar2 2/2 , Irf9 2/2 , and Stat1 2/2 cells (16) .
Although our study demonstrates IFNa/b dependence of human IL18 transcription predominantly by utilizing JAK/STAT inhibition, IFNb neutralization, and IFNa/b priming, we similarly speculate on a role of STAT1 in IL18 gene expression. Strikingly, the human IL18 promoter region (27, 28) is predicted to contain both NFkb binding sites and an accumulation of GAS (IFNg-activated sequence) elements (51) required for STAT1, STAT1a, STAT1b, and IRF-1 binding. In contrast, next to NFkb response elements, the approximately threefold larger IL1B promoter region (18, 23) contains only a few GAS elements ( Figure E6) .
Despite high frequency of potential STAT binding sites within the IL18 promoter, exclusive IFNa/b signaling did not induce IL18 expression. Similarly, IL-1b as the exclusive NFkb activator failed to initiate IL18 transcription. In contrast, flagellin as the canonical TLR5 ligand induced decreased but still detectable IL18 transcription. In line with this result, we also observed remnant IFNB expression following flagellin stimulation of human monocytes; indeed, TLR5 stimulation by flagellin has been reported to result in predominant NFkb activation but can activate the type I IFN-inducing TRIF pathway via TLR4/TLR5 heterodimers (52) . Therefore, we conclude that both STAT and NFkb activation are required to cooperate in facilitating IL18 transcription. Likewise, such unconventional transcription initiation complex assembly by both STAT and NFkb has been suggested to regulate nitric oxide synthase expression (53) . Apart from in vitro experiments on healthy donor cells, we observed LPS-stimulated monocytes with STAT1 GOF mutation to reveal distinct IL-18 expression, and ex vivo analysis of patients with systemic (hyper)inflammation demonstrated a strong correlation of type I IFN score and IL18 transcription.
Importantly, and apart from direct IFN neutralization or JAK/STAT inhibition, we observed MDAs selectively abrogating IL18 expression. This finding is of particular clinical relevance because inflammatory and autoinflammatory diseases that are marked by IL-1b and IL-18 overexpression can be treated with colchicine. In these diseases, colchicine-mediated microtubule depolymerization is thought to interfere with nonclassical release of IL-1b, IL-18, or S100 proteins and thus contribute to alleviating inflammation (54) . Recent findings suggest that colchicine specifically inhibits the pyrin inflammasome (44, 55) . However, cell stimulation with LPS and ATP, as used by us, activates the NLRP3 rather than the pyrin inflammasome (44) . Thus, both IL-1b and IL-18 are released via a pyrin-independent mechanism and secretion is unaffected by colchicine. In line with this finding, we and others observed no or an enhancing effect of MDAs on monocytic IL1B transcription (56) or IL-1b (57-60) and IL-18 release on NLRP3 inflammasome activation. Despite subsequent inhibition of IL18 transcription by colchicine, cytokine release immediately after LPS stimulation is likely constituted from the premade pool of cytoplasmic pro-and mature IL-18 (15, 16) .
In addition to inhibition of IL18 transcription, we observed that MDAs interfered with IFNb gene expression and protein release. Data from the 1970s described an effect of microtubule integrity on IFN production (46) , and recent evidence suggests that MDAs inhibit type I IFN translation and secretion (45) . Moreover, we demonstrated that blunting of IL18 expression in LPS-stimulated cells following MDA treatment can be fully rescued by IFNa/b supplementation. In support of this result, colchicine-treated patients with FMF revealed significantly decreased type I IFN scores and IL18 expression compared with patients with active sJIA disease or during or after MAS who were not exposed to colchicine.
Our findings have significant implications for clinical conditions with a hallmark of high IL-18 serum levels. Clinical experience suggests that episodes of MAS in Figure 6 . (Continued). sJIA-associated macrophage activation syndrome (MAS, n = 5), sJIA status after MAS (n = 6), or familial Mediterranean fever (FMF, n = 18). (B) Type I IFN score and IL18 expression in whole blood of colchicine-treated patients with FMF compared with active sJIA (n = 5), sJIA-associated MAS (n = 5), or sJIA status after MAS (n = 6). Data are presented as median and interquartile range and were analyzed by Mann-Whitney U test. *P , 0.05, **P , 0.01, and ***P , 0.001. (C) Wild-type mice were injected with phosphate-buffered saline (naive) or CpG on days 0, 2, 4, 6, and 8 or (D) CpG plus aIL-10R on days 0, 2, 4 and 7. (C) CpG-injected mice were treated daily with control chow (CpG Ctrl) or ruxolitinib (CpG Ruxo) starting Day 4 after the first injection. (D) Mice injected with CpG and aIL-10R were treated with vehicle control (captisol in 0.1 M citrate buffer, pH = 3.5) or ruxolitinib (90 mg/kg) twice daily starting Day 4 after the first injection. All mice were killed on Day 9 after the first CpG (plus aIL-10R) injection, and IL-18 serum levels were quantified by ELISA. Results in C and D are combined from two (C, total of 9-10 mice/group) or four (D, naive and CpG plus aIL-10R: 16-17/group; Ruxo: 18/group) independent experiments. Statistical significance was calculated using one-way ANOVA combined with the Tukey multiple comparison test. **P , 0.01, ***P , 0.001, and ****P , 0.0001. (E) Laboratory parameters and CXCL-9 and IL-18 serum levels of a treatment-refractory patient with sJIA with recurrent episodes of MAS treated with tofacitinib. JDM = juvenile dermatomyositis; SLE = systemic lupus erythematosus; WBC = white blood cell.
sJIA are associated with viral infections (29) . Intriguingly, MAS can also occur in polygenic type I interferonopathies such as SLE or JDM (61) (62) (63) . These diseases also link to type I IFN, and disease activity in SLE and JDM correlates with serum IL-18 levels (64) (65) (66) . In sJIA-associated MAS, IFNa/b signaling resulting from viral infection can come together with NFkb activation due to background inflammatory activity constituted from, for example, S100 proteins as endogenous TLR4 ligands (67) (68) (69) . In combination, this can potentiate and sustain IL-18 expression as a suggested promoter of MAS (5) . Along these lines, repeated CpG challenge to induce type I IFN expression in mice has been shown to result in MAS-like disease (70) , which can be exacerbated by increasing the bioavailability of IL-18 (6) and is sensitive to JAK/STAT inhibition (71) . In these models, TLR9 stimulation by CpG renders an otherwise survivable sepsis insult induced by mild cecal ligation and puncture or low-dose staphylococcal toxin or endotoxin overwhelmingly lethal (3, 70) . Importantly, we demonstrated that JAK/STAT inhibition in two sHLH/MAS mouse models (34, 35) greatly reduces IL-18 serum levels. We also showed that JAK/STAT inhibition successfully reduced serum IL-18 in a previously treatmentrefractory patient with sJIA who had recurrent episodes of MAS and consistently high levels of IL-18 (12) .
Linking this to our initial observations on IL-18 expression in LPS-induced immunoparalysis and endotoxin tolerance, serum IL-18 levels have been reported to increase in animals rechallenged with LPS compared with mice receiving only singleendotoxin conditioning. Importantly, priming of animals with CpG resulted in extreme overexpression of IL-18 on subsequent LPS challenge (47) . Consequently, it is conceivable that at the level of IL-18 expression, type I IFN and TLR4 signaling can cooperate in facilitating sustained or "second-wave" systemic inflammation that promotes autoinflammation-or infection-associated MAS. n Author disclosures are available with the text of this article at www.atsjournals.org.
